First results from a human trial of an experimental gene-edit therapy for Duchenne muscular dystrophy show limited benefit and detail a boy's death, according to Nature news coverage of a Cell paper, with Science giving August background on the delayed disclosure. Shanghai-based HuidaGene used a virus known as AAV to carry a base editor meant to fix DMD mutations. Four boys were treated. Two got a low dose and two got a high dose.

The boy who died received a high dose. Within a day he had severe abdominal pain and fever, then low oxygen and an irregular heartbeat, the Cell authors reported via Nature. He died of acute respiratory distress linked to the treatment, an autopsy found. HuidaGene disclosed the death in August 2025 about a year later, drawing criticism over the delay. Science reported that disclosure at the time and noted another China gene-edit death case with a different cause but a shared theme of severe immune reactions to viral delivery.

Nature said the new results show some target genes were edited but the therapy's benefit was limited. Researcher Ian Woodcock of Murdoch Children's Research Institute said large AAV doses needed to reach muscles raise immune risk. Co-founder Hui Yang said the team used drugs to calm the immune system, animal tests, and staggered dosing, yet those steps were not enough. Authors said dosing by body weight may be a poor fit when lean muscle differs from total weight.

What we know: Trial results in Cell, covered by Nature, show limited benefit and confirm a treatment-linked death in a high-dose Duchenne gene-edit patient.
What we don't: Whether safer lower-dose vectors will restore enough dystrophin in later studies.